This morning, Pr. Francis Berenbaum, Co-founder and CEO/CMO of 4Moving Biotech participated in the 35th SFR congress held from December 11th to 13th 2022, at the Parc des Expositions de la Porte de Versailles in Paris, organized by the French Society of Rheumatology.

He made an oral communication during the "Osteoarthritis" session. His presentation is entitled: "Beneficial impact of Liraglutide, a GLP1 receptor agonist, on all tissues of the knee joint in three mouse models of inflammatory and post-traumatic osteoarthritis".

‍